Rami Hannoush
Investitore di Private Equity presso Versant Venture Management LLC
Posizioni attive di Rami Hannoush
Società | Posizione | Inizio | Fine |
---|---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investitore di Private Equity | 01/02/2023 | - |
Storia della carriera di Rami Hannoush
Precedenti posizioni note di Rami Hannoush
Società | Posizione | Inizio | Fine |
---|---|---|---|
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Amministratore Delegato | - | 20/07/2023 |
Presidente | - | 20/07/2023 | |
Direttore Tecnico/Scientifico/R&S | - | 20/07/2023 | |
Fondatore | - | 20/07/2023 | |
Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. BiotechnologyHealth Technology Juvena Therapeutics, Inc. develops protein-based therapeutics that promotes tissue regeneration in the elderly. The company was founded by Hanadie Yousef and Jeremy O'connell in 2017 and is headquartered in Palo Alto, CA. | Direttore/Membro del Consiglio | 01/05/2022 | 01/03/2023 |
Mubadala Capital
Mubadala Capital Investment ManagersFinance Mubadala Capital (Mubadala Capital) is a private equity subsidiary of Mubadala Investment Co. PJSC founded in 2011. The firm is headquartered in Abu Dhabi, United Arab Emirates with offices in London, New York, Rio De Janeiro, and San Francisco. | Investitore di Private Equity | 01/09/2021 | 01/02/2023 |
Formazione di Rami Hannoush
McGill University | Doctorate Degree |
Harvard Medical School | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Canada | 2 |
Emirati Arabi Uniti | 2 |
Posizioni
Private Equity Investor | 2 |
Chief Executive Officer | 1 |
Chairman | 1 |
Settori
Consumer Services | 3 |
Finance | 3 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Mubadala Capital
Mubadala Capital Investment ManagersFinance Mubadala Capital (Mubadala Capital) is a private equity subsidiary of Mubadala Investment Co. PJSC founded in 2011. The firm is headquartered in Abu Dhabi, United Arab Emirates with offices in London, New York, Rio De Janeiro, and San Francisco. | Finance |
Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. BiotechnologyHealth Technology Juvena Therapeutics, Inc. develops protein-based therapeutics that promotes tissue regeneration in the elderly. The company was founded by Hanadie Yousef and Jeremy O'connell in 2017 and is headquartered in Palo Alto, CA. | Health Technology |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Commercial Services |
- Borsa valori
- Insiders
- Rami Hannoush
- Esperienza